IP Library Granted Patent US 10,233,424
Granted Patent B2
US 10,233,424 · App. 15/178,715 · Granted Mar 19, 2019

Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin

Inventors: Roderick A. Hyde (Redmond, WA); Wayne R. Kindsvogel (Seattle, WA); Gary L. McKnight (Bothell, WA)
Assignee: Elwha LLC
C12N5/0635A61K35/17A61K39/00C07K16/00C07K16/109C07K16/1018C07K16/1271C07K16/18C07K16/3069C07K16/44C12N15/85A61K2035/124A61K2039/505A61K2039/5156C07K2317/14C07K2317/76C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,233,424
App. No.
15/178,715
Granted
Mar 19, 2019
Kind
B2
Abstract

Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.

Claims (24)

1. An isolated modified B cell comprising:

at least one exogenously incorporated membrane immunoglobulin or a recombinant B cell receptor that is reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen;

wherein the isolated B cell is capable of expressing cytotoxicity for at least one target cell.

2. The isolated modified B cell of claim 1 , further including at least one endogenous membrane immunoglobulin reactive to the second antigen.

3. The isolated modified B cell of claim 1 , wherein the at least one exogenously incorporated membrane immunoglobulin includes one or more exogenously incorporated membrane immunoglobulin polypeptides.

4. The isolated modified B cell of claim 1 , wherein the at least one exogenously incorporated membrane immunoglobulin includes at least one exogenously incorporated nucleic acid encoding the at least one membrane immunoglobulin, wherein the cell is capable of expressing the at least one membrane immunoglobulin.

5. The isolated modified B cell of claim 1 , wherein the at least one exogenously incorporated membrane immunoglobulin includes at least two exogenously incorporated nucleic acids encoding the at least one membrane immunoglobulin.

6. The isolated modified B cell of claim 1 , wherein the isolated B cell is capable of disrupting expression of the endogenous membrane immunoglobulin reactive to the second antigen.

7. The isolated modified B cell of claim 1 , wherein the at least one exogenously incorporated membrane immunoglobulin activated by the first antigen is capable of controlling expression of the at least one endogenous secreted immunoglobulin reactive to the second antigen.

8. The isolated modified B cell of claim 1 , wherein the isolated B cell includes at least one of naïve B lymphocyte, immature B lymphocyte, transitional B lymphocyte, mature B lymphocyte, follicular B lymphocyte, memory B lymphocyte, plasmablast, or plasma cell.

9. The isolated modified B cell of claim 1 , wherein the membrane immunoglobulin includes at least one of a membrane anchor, an cytoplasmic domain, and an extracellular ligand-binding domain.

10. The isolated modified B cell of claim 1 , wherein the B cell bears at least one chimeric B cell receptor capable of transducing signals for inducing expression of cytotoxic effector molecules.

11. The isolated cell of claim 10 , wherein the cytotoxic effector molecules include at least one of perforin, granzyme B, Fas ligand, or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

12. An isolated recombinant B cell comprising:

at least one exogenously incorporated membrane immunoglobulin or recombinant B cell receptor that is reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding secreted immunoglobulin reactive to a second antigen;

wherein the isolated B cell is capable of expressing cytotoxicity for at least one target cell.

13. The isolated recombinant B cell of claim 12 further including:

at least one exogenously incorporated nucleic acid encoding membrane immunoglobulin reactive to the second antigen.

14. The isolated recombinant B cell of claim 12 further including:

at least one exogenously incorporated nucleic acid encoding a secreted immunoglobulin reactive to a third antigen.

15. The isolated recombinant B cell of claim 14 , wherein the second antigen and the third antigen are different epitopes of a single antigenic polypeptide.

16. The isolated modified B cell of claim 1 , wherein said capability of expressing cytotoxicity for a target cell includes expressing at least one of perforin, granzyme B, Fas Ligand, or TRAIL.

17. The isolated modified B cell of claim 1 , wherein said capability of expressing cytotoxicity for a target cell includes expressing at least one of perforin, granzyme B, Fas Ligand, or TRAIL upon activation of at least one receptor on the isolated modified B cell.

18. The isolated modified B cell of claim 1 , wherein the cell is part of an isolated modified B cell line.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2021
From: KOTA BIOTHERAPEUTICS, LLC
To: THE INVENTION SCIENCE FUND II, LLC
Reel/Frame 056159/0064 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2019
From: THE INVENTION SCIENCE FUND II, LLC
To: KOTA BIOTHERAPEUTICS, LLC
Reel/Frame 050995/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2019
From: ELWHA LLC
To: THE INVENTION SCIENCE FUND II, LLC
Reel/Frame 050216/0254 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: HYDE, RODERICK A.; KINDSVOGEL, WAYNE R.; MCKNIGHT, GARY L.
To: ELWHA LLC
Reel/Frame 040029/0687 →
Continuity (3)
Continuation In Part 14549685 · Nov 21, 2014
Continuation 13374351 · Dec 22, 2011
Related Publication 20160355783A1 · Dec 8, 2016